Philippe Barthélémy

Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial

Robert J. Motzer, Brian I. Rini, David F. McDermott et al. · The Lancet Oncology · 2019 · 780 citations · Full text

Medicine, Oncology, Pharmacology +12

TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors

Scott T. Tagawa, Arjun Vasant Balar, Daniel P. Petrylak et al. · Journal of Clinical Oncology · 2021 · 533 citations · Full text

Medicine, Oncology, Pharmacology +13

Conditional survival and long‐term efficacy with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma

Robert J. Motzer, David F. McDermott, Bernard Escudier et al. · Cancer · 2022 · 263 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial

Nizar M. Tannir, Laurence Albigès, David F. McDermott et al. · Annals of Oncology · 2024 · 192 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Genomics to select treatment for patients with metastatic breast cancer

Fabrice André, Thomas Filleron, Maud Kamal et al. · Nature · 2022 · 168 citations

Medicine, Bioinformatics, Oncology +12